Intact Vascular gains CE mark for endovascular stapler device; Biomet boosts Q3 sales;

@FierceMedDev: New clues on beating bugs that infect cardiac devices. News  | Follow @FierceMedDev

> Pennsylvania's Intact Vascular gained a CE Mark for its endovascular stapler device, which is used to help improve peripheral angioplasty results. Release

> German medical device and pharmaceutical companies, hospitals and nursing home operators will likely add 70,000 jobs this year, Bloomberg reports, citing a story in the Frankfurter Allgemeine Zeitung. Story

> VertiFlex has gained 5 additional patents covering the design and use of its interspinous space technology. The California company makes minimally invasive spinal surgery implants and other related tech. Release

> Boston Scientific ($BSX) is launching its Z Flex-270 steerable sheath in the U.S., designed for electrophysiology procedures to help place diagnostic and therapeutic catheters in the heart. Release

> eResearch Technology, which provides cardiac safety research for medical device, drug and biopharmaceutical companies, is going private in a $400 million deal, Reuters reports. Story

> Biomet boosted net sales to $709 million in its fiscal 2012 third quarter, the company said, up 5% versus the same period a year ago. The company's sale of sports medicine and extremity-related products grew 22% and 18%, respectively, during the quarter. Release

And Finally... More health industry taxes, anyone? The Institute of Medicine has produced a new report calling for a tax on medical care to drive improvements in the system, The Wall Street Journal's Health Blog reports. Story

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.